12:00 AM
Aug 05, 2013
 |  BioCentury  |  Finance

Financing physiocrines

aTyr aims to reach POC in rare autoimmune disorders with D round, debt deal
Financing physiocrines

aTyr Pharma Inc. could have raised more in its series D round last week, but decided to cap the financing at $49 million and instead take out a $10 million loan. The $59 million should give the company enough runway to demonstrate clinical proof of concept for its lead physiocrine program to treat rare autoimmune disorders.


Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >